Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "OPPI"

63 News Found

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs
Policy | June 03, 2021

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs

Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors

DCGI approves anti-COVID drug developed by DRDO
Policy | May 10, 2021

DCGI approves anti-COVID drug developed by DRDO

The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production

Indian vaccine players to garner Rs. 70,599 Cr in 2021
News | April 30, 2021

Indian vaccine players to garner Rs. 70,599 Cr in 2021

Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong

Latest Stories

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging